http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 20 May 2025 16:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Affimed+N.V.+++++++++++++++++++++++++++Filed+by%3A+Ridgeback+Capital+Investments+L.P./24828225.html si-local-file:///var/storage/secattach/20250520/24828225.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Affimed+N.V.+++++++++++++++++++++++++++Filed+by%3A+Ridgeback+Capital+Investments+L.P./24828225.html Tue, 20 May 2025 16:01:00 -0400 AFMD O.18625953 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Affimed+N.V.+++++++++++++++++++++++++++Filed+by%3A+Ridgeback+Capital+Investments+L.P./24828225.html si-local-file:///var/storage/secattach/20250520/24828225.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Affimed+N.V.+++++++++++++++++++++++++++Filed+by%3A+Ridgeback+Capital+Investments+L.P./24828225.html Tue, 20 May 2025 16:01:00 -0400 AFMD O.18625953 http://www.streetinsider.com/Downgrades/Cantor+Fitzgerald+Downgrades+Affimed+Therapeutics+%28AFMD%29+to+Neutral/24792838.html <p>Cantor Fitzgerald analyst Li Watsek downgraded Affimed Therapeutics (NASDAQ: AFMD) from Overweight to Neutral.</p><p>The analyst comments "Affimed disclosed initiation of insolvency proceedings under the German law due to its inability to raise capital. We had hoped for a reverse merger, a partnership, or a bridge financing on AFM13 in lymphoma and/or AFM24 in NSCLC, but it hasn't materialized in the current risk-off market environment despite multiple attempts. Any chance of a potential buyer recognizing residual value on the pipeline or the innate cell engager platform is slim, as we suspect the company has already explored this venue. We downgrade AFMD http://www.streetinsider.com/Downgrades/Cantor+Fitzgerald+Downgrades+Affimed+Therapeutics+%28AFMD%29+to+Neutral/24792838.html Wed, 14 May 2025 07:50:58 -0400 AFMD http://www.streetinsider.com/Analyst+Comments/Cantor+Fitzgerald+Downgrades+Affimed+Therapeutics+%28AFMD%29+to+Neutral/24792838.html <p>Cantor Fitzgerald analyst Li Watsek downgraded Affimed Therapeutics (NASDAQ: AFMD) from Overweight to Neutral.</p><p>The analyst comments "Affimed disclosed initiation of insolvency proceedings under the German law due to its inability to raise capital. We had hoped for a reverse merger, a partnership, or a bridge financing on AFM13 in lymphoma and/or AFM24 in NSCLC, but it hasn't materialized in the current risk-off market environment despite multiple attempts. Any chance of a potential buyer recognizing residual value on the pipeline or the innate cell engager platform is slim, as we suspect the company has already explored this venue. We downgrade AFMD http://www.streetinsider.com/Analyst+Comments/Cantor+Fitzgerald+Downgrades+Affimed+Therapeutics+%28AFMD%29+to+Neutral/24792838.html Wed, 14 May 2025 07:50:58 -0400 AFMD http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Affimed+N.V.++++++++++++++For%3A+May+14/24792662.html si-local-file:///var/storage/secattach/20250514/24792662.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Affimed+N.V.++++++++++++++For%3A+May+14/24792662.html Wed, 14 May 2025 07:16:00 -0400 AFMD O.18625953 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Affimed+N.V.++++++++++++++For%3A+May+14/24792662.html si-local-file:///var/storage/secattach/20250514/24792662.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Affimed+N.V.++++++++++++++For%3A+May+14/24792662.html Wed, 14 May 2025 07:16:00 -0400 AFMD O.18625953 http://www.streetinsider.com/Corporate+News/Affimed+%28AFMD%29+Receives+Nasdaq+Delisting+Notice/24792384.html <p>Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company’s securities from The Nasdaq Stock Market (“Nasdaq”).</p><p>The Staff’s http://www.streetinsider.com/Corporate+News/Affimed+%28AFMD%29+Receives+Nasdaq+Delisting+Notice/24792384.html Wed, 14 May 2025 06:49:13 -0400 AFMD http://www.streetinsider.com/Press+Releases/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html <p>MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist http://www.streetinsider.com/Press+Releases/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html Wed, 14 May 2025 06:45:00 -0400 A.09642568 AFMD O.18625953 O.20371933 http://www.streetinsider.com/Press+Releases/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html <p>MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist http://www.streetinsider.com/Press+Releases/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html Wed, 14 May 2025 06:45:00 -0400 A.09642568 AFMD O.18625953 O.20371933 http://www.streetinsider.com/Press+Releases/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html <p>MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist http://www.streetinsider.com/Press+Releases/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html Wed, 14 May 2025 06:45:00 -0400 A.09642568 AFMD O.18625953 O.20371933 http://www.streetinsider.com/Press+Releases/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html <p>MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist http://www.streetinsider.com/Press+Releases/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html Wed, 14 May 2025 06:45:00 -0400 A.09642568 AFMD O.18625953 O.20371933 http://www.streetinsider.com/Globe+Newswire/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html <p>MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist http://www.streetinsider.com/Globe+Newswire/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html Wed, 14 May 2025 06:45:00 -0400 A.09642568 AFMD O.18625953 O.20371933 http://www.streetinsider.com/Globe+Newswire/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html <p>MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist http://www.streetinsider.com/Globe+Newswire/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html Wed, 14 May 2025 06:45:00 -0400 A.09642568 AFMD O.18625953 O.20371933 http://www.streetinsider.com/Globe+Newswire/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html <p>MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist http://www.streetinsider.com/Globe+Newswire/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html Wed, 14 May 2025 06:45:00 -0400 A.09642568 AFMD O.18625953 O.20371933 http://www.streetinsider.com/Globe+Newswire/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html <p>MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company’s common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist http://www.streetinsider.com/Globe+Newswire/Affimed+Announces+Receipt+of+Nasdaq+Delisting+Notice/24792370.html Wed, 14 May 2025 06:45:00 -0400 A.09642568 AFMD O.18625953 O.20371933 http://www.streetinsider.com/Downgrades/H.C.+Wainwright+Downgrades+Affimed+Therapeutics+%28AFMD%29+to+Neutral/24792256.html <p>H.C. Wainwright analyst Swayampakula Ramakanth downgraded Affimed Therapeutics (NASDAQ: AFMD) from Buy to Neutral.</p> <p>For an analyst ratings summary and ratings history on Affimed Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=AFMD">click here</a>. For more ratings news on Affimed Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=AFMD&amp;type=analyst">click here</a>.</p> <p>Shares of Affimed Therapeutics closed at $0.13 yesterday.</p> http://www.streetinsider.com/Downgrades/H.C.+Wainwright+Downgrades+Affimed+Therapeutics+%28AFMD%29+to+Neutral/24792256.html Wed, 14 May 2025 06:14:35 -0400 AFMD http://www.streetinsider.com/Downgrades/Wells+Fargo+Downgrades+Affimed+Therapeutics+%28AFMD%29+to+Equal+Weight/24787906.html <p>Wells Fargo analyst Yanan Zhu downgraded Affimed Therapeutics (NASDAQ: AFMD) from Overweight to Equal Weight with a price target of $0.10 (from $11.00).</p> <p>For an analyst ratings summary and ratings history on Affimed Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=AFMD">click here</a>. For more ratings news on Affimed Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=AFMD&amp;type=analyst">click here</a>.</p> <p>Shares of Affimed Therapeutics closed at $0.69 yesterday.</p> http://www.streetinsider.com/Downgrades/Wells+Fargo+Downgrades+Affimed+Therapeutics+%28AFMD%29+to+Equal+Weight/24787906.html Tue, 13 May 2025 14:22:04 -0400 AFMD http://www.streetinsider.com/Analyst+PT+Change/Wells+Fargo+Downgrades+Affimed+Therapeutics+%28AFMD%29+to+Equal+Weight/24787906.html <p>Wells Fargo analyst Yanan Zhu downgraded Affimed Therapeutics (NASDAQ: AFMD) from Overweight to Equal Weight with a price target of $0.10 (from $11.00).</p> <p>For an analyst ratings summary and ratings history on Affimed Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=AFMD">click here</a>. For more ratings news on Affimed Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=AFMD&amp;type=analyst">click here</a>.</p> <p>Shares of Affimed Therapeutics closed at $0.69 yesterday.</p> http://www.streetinsider.com/Analyst+PT+Change/Wells+Fargo+Downgrades+Affimed+Therapeutics+%28AFMD%29+to+Equal+Weight/24787906.html Tue, 13 May 2025 14:22:04 -0400 AFMD http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Affimed+N.V.++++++++++++++For%3A+May+13/24784608.html si-local-file:///var/storage/secattach/20250513/24784608.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Affimed+N.V.++++++++++++++For%3A+May+13/24784608.html Tue, 13 May 2025 08:23:00 -0400 AFMD O.18625953 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Affimed+N.V.++++++++++++++For%3A+May+13/24784608.html si-local-file:///var/storage/secattach/20250513/24784608.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Affimed+N.V.++++++++++++++For%3A+May+13/24784608.html Tue, 13 May 2025 08:23:00 -0400 AFMD O.18625953 http://www.streetinsider.com/Corporate+News/Affimed+%28AFMD%29+Files+the+Opening+of+Insolvency+Proceedings/24784574.html <p>Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.</p><p>As previously reported, Affimed N.V. (the “Company”) has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capital. Despite its continuous and ongoing fundraising efforts, the Company has not been able to raise sufficient additional funds to continue the operations of the Company and its controlled (and wholly owned) subsidiaries Affimed GmbH http://www.streetinsider.com/Corporate+News/Affimed+%28AFMD%29+Files+the+Opening+of+Insolvency+Proceedings/24784574.html Tue, 13 May 2025 08:17:40 -0400 AFMD http://www.streetinsider.com/Press+Releases/Affimed+Announces+Filing+for+the+Opening+of+Insolvency+Proceedings/24784542.html <p>MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.</p> <p>As previously reported, Affimed N.V. (the “Company”) has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capital. Despite its continuous and ongoing fundraising efforts, the Company has not been able to raise sufficient additional funds to continue the operations http://www.streetinsider.com/Press+Releases/Affimed+Announces+Filing+for+the+Opening+of+Insolvency+Proceedings/24784542.html Tue, 13 May 2025 08:15:00 -0400 0HL9 AFMD O.00759432 O.18625953 http://www.streetinsider.com/Press+Releases/Affimed+Announces+Filing+for+the+Opening+of+Insolvency+Proceedings/24784542.html <p>MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.</p> <p>As previously reported, Affimed N.V. (the “Company”) has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capital. Despite its continuous and ongoing fundraising efforts, the Company has not been able to raise sufficient additional funds to continue the operations http://www.streetinsider.com/Press+Releases/Affimed+Announces+Filing+for+the+Opening+of+Insolvency+Proceedings/24784542.html Tue, 13 May 2025 08:15:00 -0400 0HL9 AFMD O.00759432 O.18625953 http://www.streetinsider.com/Press+Releases/Affimed+Announces+Filing+for+the+Opening+of+Insolvency+Proceedings/24784542.html <p>MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.</p> <p>As previously reported, Affimed N.V. (the “Company”) has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capital. Despite its continuous and ongoing fundraising efforts, the Company has not been able to raise sufficient additional funds to continue the operations http://www.streetinsider.com/Press+Releases/Affimed+Announces+Filing+for+the+Opening+of+Insolvency+Proceedings/24784542.html Tue, 13 May 2025 08:15:00 -0400 0HL9 AFMD O.00759432 O.18625953 http://www.streetinsider.com/Press+Releases/Affimed+Announces+Filing+for+the+Opening+of+Insolvency+Proceedings/24784542.html <p>MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.</p> <p>As previously reported, Affimed N.V. (the “Company”) has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capital. Despite its continuous and ongoing fundraising efforts, the Company has not been able to raise sufficient additional funds to continue the operations http://www.streetinsider.com/Press+Releases/Affimed+Announces+Filing+for+the+Opening+of+Insolvency+Proceedings/24784542.html Tue, 13 May 2025 08:15:00 -0400 0HL9 AFMD O.00759432 O.18625953